

## Board regular items and responsibilities

<p><b>Chief Executive's report</b></p> <ul style="list-style-type: none"> <li>Operational update from the business divisions</li> <li>New greenfield opportunities and partnerships</li> <li>Issues arising across the Group</li> </ul>	<p><b>Committee reports</b></p> <ul style="list-style-type: none"> <li>Committee Chair updates on business of the Committee</li> <li>Discussion of recommended actions</li> <li>Delegation of issues to management</li> </ul>	<p><b>Investors and markets</b></p> <ul style="list-style-type: none"> <li>Capital and pharmaceutical markets updates</li> <li>Market consensus information</li> <li>Investor relations annual review</li> </ul>
<p><b>Legal</b></p> <ul style="list-style-type: none"> <li>Regulatory issues</li> <li>Litigation developments</li> <li>Legal compliance updates</li> <li>Legal and regulatory updates</li> </ul>	<p><b>Strategic</b></p> <ul style="list-style-type: none"> <li>Business environment updates</li> <li>Pharmaceutical market strategy</li> <li>Specific M&amp;A opportunities</li> </ul>	<p><b>Risk</b></p> <ul style="list-style-type: none"> <li>Risk appetite</li> <li>Principal risks</li> <li>Deep dive assessments</li> <li>Management framework</li> </ul>
<p><b>Finance</b></p> <ul style="list-style-type: none"> <li>Financial reporting</li> <li>Flash sales</li> <li>Forecasting</li> <li>Budgeting</li> </ul>	<p><b>Governance</b></p> <ul style="list-style-type: none"> <li>Board process enhancements</li> <li>UK and listed environment developments</li> <li>Annual governance review</li> </ul>	<p><b>Training</b></p> <ul style="list-style-type: none"> <li>Company specific training</li> <li>Professional adviser opportunities</li> <li>Bespoke training programmes</li> </ul>